Publication: 2769

Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials

Citation:: Cancer Res vol 78 (4 Supplement) GS4-02

Meeting Instance:: SABCS 2017
Year:: 2018
Type:: Abstract
Sub type:: Oral
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 2920

Program:: OGC
Primary Committee:: Breast
Sec. Committees:

Pharmas:
Grants:: U10CA180821

Corr. Author:
Authors:: Olivia Pagani Meredith M. Regan Gini F. Fleming Barbara A. Walley Marco Colleoni István Láng Henry L. Gomez Carlo Tondini Harold J. Brustein Matthew P. Goetz Eva M. Ciruelos Vered Stearns Hervé R. Bonefoi Silvana Martino Charles E. Geyer Jr. Graziella Pinotti Alan S. Coates Aron Goldhirsch Richard D. Gelber Prudence A. Francis

Networks:: LAPS-IL057, LAPS-MD017, LAPS-MN026, LAPS-PA015, OH070, UPSTATE

Study
Multiple Studies, or Legacy Studies in Alliance Study:: IBCSG-24-02 (SOFT-TEXT), IBCSG-25-02 (TEXT)
Phases:: 3

Keywords: